Manuscript no. HAEMATOL/2010/034405 entitled “A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload

Authors: Hugh Young Rienhoff Jr., Vip Viprakasit, Lay Tay, Paul Harmatz, Elliott Vichinsky, Deborah Chirnomas, Janet L. Kwiatkowski, Amy Tapper, William Kramer, John B Porter, and Ellis J. Neufeld

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
   • Hugh Young Rienhoff Jr, FerroKin BioSciences, Inc., hugh@ferrokin.com
   • Ellis J. Neufeld, Hematology, Children's Hospital Boston, ellis.neufeld@childrens.harvard.edu

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 …………………… Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study: Hugh Young Rienhoff, Jr., FerroKin BioSciences, Inc., hugh@ferrokin.com

3) Design & Methods. The following authors were responsible for specific investigations (please detail):
   • The following authors were responsible for specific investigations protocol design:
     - Hugh Young Rienhoff, Jr., FerroKin BioSciences, Inc., hugh@ferrokin.com
     - Ellis J. Neufeld, Hematology, Children's Hospital Boston, ellis.neufeld@childrens.harvard.edu
     - John Porter Haematology, University College London, j.porter@cancer.ucl.ac.uk
     - Elliott Vichinsky, Children's Hospital & Research Center Oakland, EVinchinsky@mail.cho.org
     - Paul Harmatz, Children's Hospital & Research Center Oakland, PHarmatz@mail.cho.org
   • The following author was responsible for coordinating chemical and material control (CMC) and analytic chemistry:
     - Amy Tapper FerroKin BioSciences, Inc., amy@ferrokin.com
   • The following authors were responsible for data analysis including pharmacokinetics:
     - Hugh Young Rienhoff, Jr., FerroKin BioSciences, Inc., hugh@ferrokin.com
     - William Kramer, FerroKin BioSciences, Inc. bill@kramer-consulting.com
   • Name Surname was/were responsible for recruiting patients to the study:
     - Ellis J. Neufeld, Hematology, Children's Hospital Boston, ellis.neufeld@childrens.harvard.edu
     - John Porter Haematology, University College London, j.porter@cancer.ucl.ac.uk
     - Elliott Vichinsky, Children's Hospital & Research Center Oakland, EVinchinsky@mail.cho.org
     - Paul Harmatz, Children's Hospital & Research Center Oakland, PHarmatz@mail.cho.org
4) Results. The following authors were responsible for specific portions of the results, including figures and tables
- Hugh Young Rienhoff, Jr., FerroKin BioSciences, Inc., hugh@ferrokin.com
- William Kramer, FerroKin BioSciences, Inc. bill@kramer-consulting.com

5) Writing the manuscript. The following author was responsible for writing the manuscript:
- Hugh Young Rienhoff, Jr., FerroKin BioSciences, Inc., hugh@ferrokin.com

Contributors Listed in Acknowledgments:
The authors would like to thank Amber Jones, Maggie Neptune, Jennifer Peppe, and Laura Eichorn of FerroKin BioSciences; Jennifer Braunstein and Pamela Boardman of Children’s Hospital, Boston; Jacqueline Madden of Children’s Hospital & Research Center Oakland; Sage Green of Children’s Hospital of Philadelphia. This study was sponsored by FerroKin BioSciences and was supported, in part, with funds provided by the National Center for Research Resources grant, UL1RR024131-01 (Paul Harmatz). Vip Viprakasit received supports from the Thailand Research Fund and BIOTEC, Thailand. Ellis Neufeld and Paul Harmatz received research support from FerroKin BioSciences and Novartis.